Eisai Licenses Cancer Drugs To Bioventures To Develop
This article was originally published in PharmAsia News
Executive Summary
Eisai licensed two cancer drugs it had withdrawn from development after Phase I trials to a pair of bioventures to use their particular skills to get them to market.